Press Releases

Please Select Year

Advanced Accelerator Applications Announces Start of Phase III Study Investigating Radioligand Therapy Lutathera® as First-Line Treatment in Patients with Advanced GEP-NETs

Mar 25, 2020

Advanced Accelerator Applications Announces State of Israel Ministry of Health Approval for Lutathera®, in the Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Jul 29, 2019

Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare® for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium (177Lu) Oxodotreotide (Lutathera®)

Jun 5, 2019

Advanced Accelerator Applications Announces Health Canada Approval for Lutathera™, a Treatment for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Feb 7, 2019

Novartis successfully completes acquisition of Endocyte

Dec 21, 2018

Advanced Accelerator Applications signs exclusive option and license agreement with FUJIFILM Toyama Chemical to develop and commercialize radiolabeled FF-10158 for oncology indications

Dec 3, 2018

Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden

Oct 19, 2018

Advanced Accelerator Applications Announces First Patients Dosed in Two Clinical Studies with PSMA-R2 for Prostate Cancer – Second Theragnostic Program for Oncology Enters the Clinic

Jun 22, 2018

Novartis announces JCO publication of Lutathera® NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs

Jun 7, 2018

Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer

Feb 12, 2018

Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer

Feb 1, 2018

Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

Jan 26, 2018

Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer

Jan 22, 2018

Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer

Dec 7, 2017

Advanced Accelerator Applications Board of Directors Recommends $3.9 Billion All Cash Tender Offer by Novartis

Dec 5, 2017

Media Contacts

Rachel Levine
Global Head of Communications and Patient Advocacy

Veronique Mermet
Global Communications Specialist
+33 (0)4 50 99 30 70